GlassScriptPhysician profile
Zev Aaron Allison
NPI 1952930513
$4,255.44
in general payments reported to CMS, 2019-2025
23 companies · $2,754 in 2025
The $2,754 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,501 · 2025: $2,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,019 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150 · Gift: $86.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,018.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
| Gift | $86.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $839.36 | 2025 | Rapiblyk |
| Abiomed | $641.95 | 2024-2025 | Impella |
| Shockwave Medical, INC | $366.94 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Heartflow, INC. | $338.78 | 2024-2025 | |
| Edwards Lifesciences Corporation | $295.23 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $229.25 | 2024-2025 | |
| Boston Scientific Corporation | $226.94 | 2025 | Avvigo Guidance System |
| Pfizer INC. | $208.54 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $203.34 | 2024-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $158.30 | 2024-2025 | |
| Eko Health, INC. | $150.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $110.91 | 2025 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $92.03 | 2024-2025 | Wainua, Andexxa |
| Merck Sharp & Dohme LLC | $76.52 | 2024-2025 | Winrevair, Verquvo |
| Janssen Pharmaceuticals, INC | $57.36 | 2024 | Xarelto |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $56.83 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $49.29 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $31.63 | 2025 | |
| Invivyd INC | $31.36 | 2025 | Pemgarda |
| Terumo Medical Corporation | $29.13 | 2025 | Tr Band, Angio-Seal |
| Altathera Pharmaceuticals LLC | $27.60 | 2024 | Sotalol Hydrochloride |
| Bridgebio Pharma, INC. | $18.94 | 2025 | Attruby |
| Cardiva Medical, INC. | $15.21 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zev Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.